Current Press Releases

Shift Pharmaceuticals, CMTA Partner On ASO Treatment for CMT1A – November 2022

Shift Pharmaceuticals receives funding from the National Institute of Neurological Disorders and Stroke – May 2022

Archives

2020

FDA grants Orphan Drug status for Shift’s lead compound for SMA – May 2020

Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A
treatment – February 2020

2019

The Gwendolyn Strong Foundation and National Institute of Health fund Shift Pharmaceuticals – December 2019

2018

Congressional Directed Medical Research Program (CDMRP) awards grant to Shift for the company’s lead compound for SMA – November 2018